Antigen Detection Brand Ranking

Guangzhou Sonostar Technologies Co., Limited

Sonostar Technologies Co., Limited is specialized in R&D, production and sales. We provide state-of-the-art medical equipment ranging from ultrasound equipment to patient monitoring, ophthalmic, dental and respirator equipment. We insist on making modern medical technology affordable without compromising quality. We have extensive experience offering ODM and OEM services for many domestic and overseas enterprises, and we began entering international markets in recent years. Our motto and aim is "New Tech, New Life". And we mean it. As a company, we strive to popularize and utilize advanced technology, thus benefitting patients, their families and medical professionals alike. Our friendly costumer service is ready to help in the case of any questions or concerns. We warmly welcome potential business partners and the medical community to join hands with us in our endeavour to make the world a better place. Our main products:Ultrasound Scanner,Probe Type Ultrasound Scanner,B/W Ultrasound Scanner ,Vet Ultrasound Scanner, Ophthalmology Scanner ect.

Wondfo Biotech Co., Ltd.

Guangzhou Wanfu Biotechnology Co., Ltd. (stock code: 300482) was founded in 1992 and is headquartered in Guangzhou Science City. It was listed on the Shenzhen Stock Exchange GEM on June 30, 2015. Wanfu Bio's business is concentrated in the field of in vitro diagnosis under the medical device sector, specializing in the research and development, production and intelligent manufacturing, marketing and services of fast diagnostic reagents and supporting instruments of instant testing/bedside testing. It is a domestic POCT One of the leading companies. The products are sold to more than 140 countries and regions around the world and are widely used in clinical testing, critical and severe diseases, chronic disease management, primary medical care, epidemic monitoring, disaster rescue, on-site law enforcement and family personal health management. Wanfu Bio has successively won the National Torch Program Key High-tech Enterprise, National Enterprise Technology Center, National Bioengineering High-tech Industrialization Demonstration Base, National Intellectual Property Advantage Enterprise, World Health Organization PQ Certified Enterprise, and World Customs Organization AEO Senior Certified Enterprise. One of the domestic in vitro diagnostic reagent companies that have passed the on-site audit of the US FDA. The company currently has set up R&D centers in Guangzhou, Shenzhen, China, and San Diego, USA. It has more than 800 R&D personnel, all of which are professionals in the fields of biochemistry, clinical medicine, microelectronics technology, etc. The intensity of R&D investment and R&D team strength are both in the industry's advanced position. After 30 years of development, the company has built a relatively complete technology platform and product line, and is an enterprise with a wide range of technology platform layouts and rich product lines among domestic POCT enterprises. The company has existing immunocolloid gold technology platform, immunofluorescence technology platform, electrochemical technology platform, dry biochemical technology platform, chemiluminescence technology platform, molecular diagnostic technology platform, pathological diagnosis technology platform, as well as instrument technology platform and biological raw material platform, and Relying on the above nine technical platforms, a rich product line has been formed in the field of cardiovascular and cerebrovascular diseases, inflammation, tumors, infectious diseases, viral testing (drug abuse), eugenics and other testing fields. As of December 31, 2021, the company has obtained a total of 540 product registration certificates such as NMPA, FDA, CE, and Canadian MDALL, ranking among the top in the industry.

Beijing Hotgen Biotech Co., Ltd.

Beijing Rejing Biotechnology Co., Ltd., established in June 2005, is a bio-high-tech enterprise with the mission of "developing biotechnology and benefiting human health". The company continues to explore independent innovation diagnostic technology platforms, actively develop and expand liquid biopsy cancer early screening technology, and establish a multiomic diagnostic technology platform including protein markers, sugar chain exosomes, and DNA methylation; at the same time, it established the Future Technology Research Institute , explore cutting-edge technologies, actively deploy biopharmaceutical fields such as antibody drugs, live bacteria drugs, exosome drugs, and create a full-industry chain development strategy from diagnosis to treatment. In the field of clinical diagnosis, the company has a number of cutting-edge innovative technologies and innovative products; after years of development, the company has built a bioactive raw material research and development platform, sugar capture technology platform, magnetic microparticle chemiluminescence technology platform, and upper forwarding technology platform in the field of clinical diagnosis. , colloidal gold immunochromatography technology platform, enzyme-linked immunology technology platform, molecular diagnostic technology platform, instrument R&D technology platform, etc.; establish a high-precision forwarding POCT (UPT series) platform to small and medium-sized The strategic layout of fully automatic single-person chemiluminescence platform (MQ60 instrument series), and then to the large high-throughput fully automatic chemiluminescence platform (C900, C2000, C3000), has realized the immune diagnosis from the primary medical market to the high-end medical market. Corporate strategy with full-scenario application as the goal.公司检测菜单已涵盖炎症感染、心脑血管、骨代谢、甲功激素、糖尿病、高血压、肝炎肝癌、其他肿瘤等多种疾病的检测；并已实现单人份检测在国内基层医疗市场大范围Promote and apply it and the application of "triple test products for early diagnosis of liver cancer (AFP, AFP-L3%, DCP)" in most large benchmark tertiary hospitals. As one of the companies that obtained market access to the new crown antigen self-test products in Germany in 2021, the company has always practiced the core value of "quality determines the life and death of the company" and continued to provide excellent product supply to the global market; the new crown self-test reagent has been obtained one after another. EU CE, Germany BfArM, France ANSM, UK MHRA, Thailand TFDA, Singapore Health Sciences Bureau HSA, Brazil Health Bureau ANVISA and other major global registrations/registrations, exported to Germany, France, Italy, Austria, Hong Kong, Singapore, Vietnam, Thailand, Brazil, Peru and other nearly 40 countries and regions around the world are widely recognized and have become the mainstream products in the European home self-test market. The company continues to expand its business and set up subsidiaries or offices in key markets such as Europe, India, and the Americas. The company was listed on the Science and Technology Innovation Board in 2019. The company has always focused on technological innovation, continuously explored new diagnostic technologies and discovered new diagnostic markers; at the same time, it has continuously explored new business areas and accelerated its in-depth layout in the field of biopharmaceuticals.

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

Beijing Wantai Biopharmaceutical Co., Ltd. (hereinafter referred to as Wantai Biopharmaceutical) was established in 1991. It is a high-tech enterprise engaged in the research and development and production of biological diagnostic reagents and vaccines. With the pursuit of "contributing to the cause of human health", the company is committed to transforming biotechnology achievements into high-quality products to serve the public. The company has seven subsidiaries, and its products cover multiple fields such as enzyme rabbits, colloidal gold, chemiluminescence, nucleic acid detection, biochemistry, vaccines and quality control products. In 2005, with the approval of the Ministry of Science and Technology, Yangshengtang Wantai Biology and Xiamen University jointly established the National Center for Diagnostic Reagents and Vaccine Engineering Technology (NIDVD). The center has built an indispensable bridge between product research and development and industrialization, becoming an industrial incubator that effectively undertakes relevant R&D achievements across the country and even internationally, accelerating the speed of diagnostic reagents and vaccine research and development products entering the market, and shortening the product transformation cycle. This has made great progress in China's infectious disease diagnostic reagents and vaccine industries. Beijing Wantai Biopharma Co., Ltd. takes "science-based, health-oriented" as its corporate development concept, adheres to the purpose of "survival with quality and development with scientific and technological innovation", and is committed to contributing to the cause of human health. It will also write a brilliant chapter in the development history of China's diagnostic reagents and vaccines!

Jiangsu Bioperfectus Technologies Co., Ltd.

Jiangsu Shuoshi Biotechnology Co., Ltd. was founded in 2010 and is located in China Pharmaceutical City, Taizhou, Jiangsu. It was listed on the Shanghai Stock Exchange Science and Technology Innovation Board on December 5, 2019 with the stock code 688399. Shuoshi Biosciences takes molecular diagnostic technology as the core and is a national high-tech enterprise integrating diagnostic reagents, instruments, and third-party medical testing services. It has now become a benchmark enterprise in the domestic molecular diagnostic industry. The company has two clean production workshops that comply with the national medical device production quality management standards, and has passed the ISO13485 quality system certification; it has the honorary title of "innovation and entrepreneurship" talent of the Ministry of Science and Technology and the "Double Entrepreneurship Team" of Jiangsu Province. In terms of products, the company has multiple modern biological technology platforms such as multi-fluorescence quantitative PCR and enzyme chemistry, and is engaged in product research and development, production and sales in the fields of disease prevention and control, female reproductive tract microecology detection and tumor screening. Nearly 500 products have been successfully developed, including infectious disease pathogen detection, female reproductive tract microecology detection, and tumor screening. Many products have obtained Class III or Class II product registration certificates issued by the Drug Administration. In the field of disease prevention and control, the company is an important supplier of nucleic acid testing products for disease control, in the prevention and control of H7N9 avian influenza virus in 2013, Ebola virus outbreak in West Africa in 2014, and the new coronavirus pneumonia outbreak in 2020. , all made very important contributions. In the field of clinical testing, the company is an important supplier of microecological testing products for women's lower reproductive tract. In the future, the company will continue to uphold the mission of "Shuoshi Diagnosis, for health", and guided by the corporate culture of "quality, efficiency, fairness and justice", to provide customers with good products and perfect services.

Jilin Sinoscience Technology Co. LTD

Jilin Sinoscience Technology Co. LTD is a high & new technology enterprise, specializing in research, production, sales, and service of clinical diagnostics products. We are established in Changchun in 2021. Our main products are In vitro diagnostics reagent and instruments. We have more than 70 items of reagent in IVD field, and continue to develop Auto-Chemistry Analyzer, urinalysis products and so on. We are committed to be one of the best suppliers in IVD industry, with advanced technology, top quality and offer various series products. At the same time, we also want to become a third-party medical testing center, which provide regional medical testing service, equipping with self-developed regional LIS system, modern disinfection center, Cold Chain Logistics system, Cloud Platform and other supporting system. Aim Technological innovation, benefiting human beings, chasing our dreams, constructing China together! It is our service aim. Sinoscience has a professional service team and high - effective service awareness, we will provide our customers with dedicated technology service, and we will be one of the professional suppliers with perfect service system. Vision Sinoscience are committed to be a supplier with medical testing integrated System in China and provide customers the laboratory whole solutions. We will launch a series of high-tech products and make a contribution to IVD field development and human health. Mission Technological innovation, building Chinese dream! Sinoscience constantly bring forth new ideas and develop high quality products with advanced technology and perfect system, to help to fulfill Chinese dream. Values Professional service, customer first Sinoscience offers the best service as a high-tech enterprise. We focus on the human health, and create hope for lives.

Hangzhou DIAN Biotechnology Co., Ltd.

DIAN Diagnostic Group Co., Ltd., founded in 1996 and was listed in 2011 (China stock code: 300244), is committed to providing integrated solutions for medical diagnostics, with third-party diagnostic services as its core business. Hangzhou DIAN Biotechnology Co., Ltd. (GENEDIAN), holding subsidiary of DIAN Diagnostics, is a high-tech IVD enterprise providing one-stop solutions of "reagent + instrument+ digital intelligent system" for clinical and laboratory in molecular diagnostic and pathological diagnostic area. DIAN Biotech is devoted to in-house R&D, manufacture, international sales and technical service. Its factory is ISO 13485 certified and complies to GMP standards, and it is equipped with 11,000 m² factory size for production, over 11 automated production lines to ensure annual production capacity up to 600 million tests. Served over 17,000 medical institutions all over China, DIAN Biotech is exploring international market with its digital and Ai-assisted pathology diagnostic solutions for worldwide health concern.

Acon Biotech (Hangzhou) Co., Ltd.

Aikon On •Call® is a brand launched by Aikon Biotechnology (Hangzhou) Co., Ltd. in 2004 specifically targeted patients and doctors with chronic diseases. Aike integrates biology, medicine, electronics, information and other technologies, with blood sugar detection as the core, and its products cover four major chronic diseases, including diabetes, hypertension, hyperlipidemia, and hyperuric acid, as well as cardiovascular diseases, thyroid diseases, respiratory diseases, A number of testing indicators in the fields of kidney disease and other fields provide a variety of simple, fast and accurate testing solutions for patients with various chronic diseases. Aike is committed to building a full network system for chronic disease prevention and control, providing overall solutions for chronic disease patients around the world. With its deep understanding of chronic disease management and the advantages of product research and development accumulated over the years, Aike has become the first key brand for medical staff and related chronic disease educators around the world. Keeping health online is Aike’s promise to patients. We have established in-depth cooperation with medical institutions at all levels and major chain pharmacies across the country, providing professional health consultation and product training before sales; providing product lifelong warranty services after sales, and building a scientific self-health management platform for chronic disease patients. Aike serves every user with a scientific attitude, professional level and standardized system.

Zhejiang Orient Gene Biotech Co., Ltd.

Zhejiang Oriental Gene Biologics Co., Ltd. was established in December 2005. It is a company specializing in the research, development, production and sales of in vitro diagnostic products. It belongs to the field of high-end medical equipment and devices. Currently, the main product POCT instant diagnostic reagent is mainly used in infectious disease detection (including new coronavirus testing products), drug testing, eugenics and eugenicity testing, tumor marker testing and myocardial marker testing, among which infectious disease detection and drug testing are The company's two core product series. The company's sales network is in more than 120 countries and regions, and overseas sales revenue accounted for 95% in 2019. At present, the company has obtained more than 300 overseas certifications/registrations and more than 70 domestic registration/registration certificates.

Vazyme Biotech Co., Ltd.

Norwich is a biotechnology enterprise focusing on technical research and development and product development of functional proteins such as enzymes, antigens, antibodies, and polymer organic materials. Relying on the independently established key common technology platforms, it has successively entered the business fields of life sciences, in vitro diagnosis, biomedicine, etc. It is one of the few R&D and innovative enterprises in China that have both independent and controllable upstream technology development capabilities and terminal product production capabilities, and is committed to Intelligent manufacturing of "biochips" continues to inject new vitality into the development of the biotechnology industry. Innovation and R&D capabilities and talent reserves Novizan has always adhered to innovation and is committed to breakthroughs. It insists on starting research and development from the source of technology. Relying on independent core technologies, it builds a key common technology platform that can quickly, efficiently and on a large scale. It has more than 600 genes. It has key raw materials such as engineering recombinases and more than 2,500 high-performance antigens and monoclonal antibodies. It has more than 2,000 terminal products and can be widely used in scientific research, high-throughput sequencing, in vitro diagnosis, medicine and vaccine research and development, and animal quarantine. A strong talent team is the support of R&D strength. Norwich has a R&D innovation team of nearly 700 people, composed of composite R&D personnel in various fields such as molecular biology, enzymatics, immunology, bioinformatics, organic chemistry and materials science, of which 67% of R&D personnel have Master's degree or above. Master the core technology of raw materials and gather downstream industry advantages Since its establishment, Novozan has always adhered to the business philosophy of R&D as the core, relying on independent core technologies, constantly updated and iterated technology and upgraded, and opened up new business areas. Through years of hard work, Novozan has achieved technical achievements in the field of biomedicine. It has successfully launched biological reagents including high-throughput sequencing library construction series, PCR series, qPCR series, molecular cloning series, reverse transcription series, Bio-assay and other series, as well as cardiovascular and cerebrovascular, inflammatory infection, eugenics and gastric system. 9 series of POCT diagnostic reagents including function and nervous system, and have formed a variety of customer groups including scientific research institutions, high-throughput sequencing service enterprises, molecular diagnostic reagent manufacturers, pharmaceutical enterprises, CRO enterprises, hospitals and other medical institutions. Customer portfolio. Don't forget your mission and fulfill your responsibilities While expanding and deepening the product and technology chain, Novozan has always adhered to the mission of "technology to achieve healthy life", constantly developing new technologies and providing high-quality products and professional services around the "discovery-diagnosis-prevention-treatment" of diseases. , create value for customers. Norwich is based on the strugglers and provides employees with a broad development platform, attracting outstanding talents from all over the country and even the world to join, and promoting the overall development and improvement of China's biomedical technology industry. Novizan actively participates in the construction of public health, uses technology to help national biosecurity construction, and helps mankind overcome major infectious diseases, tumors, and autoimmune diseases!

Wuhan Mingde Biotech Co., Ltd.

Wuhan Mingde Biotechnology Co., Ltd. (002932.SZ) was established in 2008 and is located in Wuhan Optical Valley Bio-City, a national biological industry base. It is a company focused on the independent research and development, production and sales of in vitro diagnostic products, providing five major centers. The national high-tech enterprise of medical informationization overall solutions and third-party medical testing services. After years of technological accumulation, a rich product matrix supported by 10 major technology platforms has been built, covering the product lines of immune, blood gas, and molecular diagnosis, forming an area with immediate and accurate diagnosis products as the cornerstone and emergency and critical illness information system as the bridge. An overall solution for collaborative treatment-based smart diagnosis can realize the full process layout of pre-hospital, intermediate and post-hospital. Currently, the business has covered 7,500 medical institutions in 30 provinces, municipalities and autonomous regions across the country, providing product services and technical support to more than 50 countries and regions around the world. Mingde Biology focuses on the treatment of critical and critical care, in line with the new requirements of national emergency emergency services, and provides medical institutions with an overall solution of "emergency and critical care information management platform + inspection and inspection equipment + center certification consultation + normalized operation" to achieve "prevention, The full process management of rescue, treatment and health will help the intelligent transformation and upgrading of the five major centers in the country and the construction of special disease prevention and control system. After years of deep cultivation and adhering to the customer-centric service concept, Mingde has not only won the recognition of customers, but also gained high recognition from the industry . Mingde Bio attaches great importance to technical accumulation and product R&D innovation, has an independent R&D center and a high-tech R&D team. It currently has more than 1,200 employees and an elite R&D team with a return doctoral degree as the core. Degrees account for more than 30%, and R&D investment in 2022 exceeds 388 million. Up to now, Mingde Biologics has obtained more than 200 registration certificates for Class II and III medical device, and has more than 100 independent intellectual property rights, including core invention patents, software works, etc. More than 100 products have passed the EU CE certification and NMPA certification. After years of deep cultivation, Mingde Biotech has developed into a cutting-edge supplier of comprehensive in vitro diagnostic solutions in China. It has successively won the honors of "National Specialized and New Small Giant Enterprise Award", "National Enterprise Technology Center", "National Science and Technology System Fighting the New Coronavirus Epidemic-Advanced Collective", and "Top 100 Chinese Pharmaceutical Influential Enterprises". Mingde Biology will continue to provide high-quality products and services for human health, create a closed service loop centered on human medical and health needs, and always practice the mission of allowing everyone to enjoy health.

Shenzhen Huirong Medical Co., Ltd.

Shenzhen Yahuilong Biotechnology Co., Ltd. (hereinafter referred to as "Yahuilong") was established in 2008 and is a listed company on the Science and Technology Innovation Board (stock code: 688575). The company is headquartered in Baolong Science and Technology City, Baolong Street, Longgang District, Shenzhen. Yahuilong is mainly engaged in the research, development, production, sales and services of in vitro diagnostics (IVD) products in the biopharmaceutical industry. It is a national high-tech enterprise with a large number of independent intellectual property rights and is also a national intellectual property demonstration enterprise. In the first half of 2022, the group's output value was 3.15 billion yuan and tax payments of 105 million yuan. Yahuilong focuses on R&D and innovation in the field of in vitro diagnosis. It currently has more than 1,500 employees, and the proportion of R&D personnel exceeds 25%. It currently has chemiluminescence, fluorescence immunochromatography, enzyme-linked immunization, immunoblotting, indirect immunofluorescence, colloidal gold The six major in vitro diagnostic technology platforms for immunochromatography, and their products cover business areas such as autoimmunity, infection immunity, liver disease detection, reproductive health, and respiratory testing. More than 300 products are widely used in medical institutions such as hospitals, health centers, community outpatient clinics and third-party testing centers at all levels, and the domestic tertiary hospitals account for more than 56%. While based in the domestic market, Yahuilong is actively developing international markets. Its products have been exported to more than 100 countries and regions in Europe, the Middle East, Southeast Asia, Africa, Australia and the Americas, and have been favored and recognized by global customers. Yahuilong insists on independent innovation, is guided by market demand and customer service as the purpose, and has established an industrial chain layout from raw material research and development to reagent research and development to production. Over the past decade, Yahuilong has undertaken major scientific and technological projects such as the National Development and Reform Commission, the Ministry of Science and Technology, the Shenzhen Development and Reform Commission, the Shenzhen Industry and Information Technology Bureau, and the Shenzhen Science and Technology Innovation Commission. Among them, "High-throughput fully automatic immunoassay device" and The project of R&D and Industrialization of Supporting Reagents has been approved by the National Development and Reform Commission, and has been approved as a major project in Shenzhen and a key introduction project in Longgang District for four consecutive years. As of June 30, 2022, the company has obtained 133 domestic authorized patents and 17 international patents, accounting for 70% of the patents applied for, and accounting for 50% of the authorized patents. The company attaches great importance to the cultivation of talent echelons, and has successively worked with the team of Academician Zhuang Hui of Peking University, Academician Yan Xiyun of the Institute of Biophysics of the Chinese Academy of Sciences, Academician Tang Benzhong of the Chinese University of Hong Kong (Shenzhen), Dean Lu Hongzhou of Shenzhen Third People's Hospital, and Southern University of Science and Technology Academician Gu Dongfeng's team, the National Optoelectronics Laboratory of Huazhong University of Science and Technology, the National High-Performance Medical Device Innovation Center and other scientific research institutes and medical institutions cooperate to establish joint laboratories and carry out technical product research. In addition, Yahuilong has also established a training platform for medical testing innovative talents with well-known universities such as Huazhong University of Science and Technology, Guangdong Medical University, and Hunan University of Technology, jointly train master's and doctoral students, and jointly cultivate high-level professional talents. The company adheres to the mission of "focusing on life and health, striving to make technology benefit mankind", always pursues excellence, constantly provides excellent products and services for the cause of human health, and strives to become a leading enterprise in the field of immunity and an advanced enterprise in global in vitro diagnosis.

Thermo Fisher Scientific (China) Co., Ltd.

Thermo Fisher Technology is a world leader in the field of scientific services, with annual sales exceeding US$30 billion. The company ’s mission is to help customers make the world healthier, cleaner and safer. Help customers accelerate research in the field of life sciences, solve complex problems and challenges encountered in the field of analysis, promote the development of medical diagnosis and treatment, and improve laboratory productivity. More than 80,000 Thermo Fisher employees around the world will provide customers with advanced innovative technologies, convenient procurement solutions and multi-faceted services through a series of industry-leading brands Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. Thermo Fisher Technology China In 1982, Thermo Fisher set up its first sales office in China, with its headquarters in Shanghai in China, and has established branches in Beijing, Guangzhou, Hong Kong, Chengdu, Shenyang, Xi'an, Nanjing, Wuhan, Jinan, Dongguan and other places. . The products mainly include analytical instruments, laboratory equipment, reagents, consumables and software, etc., provide comprehensive laboratory solutions to serve customers from all walks of life. In order to meet the needs of the Chinese market, the current eight factories are operated in Shanghai, Beijing, Suzhou and Guangzhou respectively. 6 application development centers and demonstration laboratories have been established nationwide to bring world-leading technologies and products to Chinese customers, and provide many services such as application development and training; China Innovation Centers located in Shanghai and Suzhou have more than 100 Professional researchers and engineers and more than 100 patents. The Innovation Center focuses on product research and development in vertical markets, combining the needs of the Chinese market and advanced technologies at home and abroad, and develops technologies and products suitable for Chinese users.

Cepheid (a Danaher company)

Cepheid is renowned for its GeneXpert System, which includes antigen tests for rapid and accurate infectious disease detection.

LumiraDx Limited

LumiraDx offers innovative antigen tests like the LumiraDx SARS-CoV-2 Ag Test, known for its portability and rapid results.

bioMérieux SA

BioMérieux is a leader in in vitro diagnostics, offering antigen tests like the BIOFIRE SPOTFIRE System for rapid and accurate results.

Quidel Corporation

Quidel specializes in rapid diagnostic testing, with products like the Sofia SARS Antigen FIA, widely used for COVID-19 screening.

SD Biosensor, Inc.

SD Biosensor offers a wide range of blood glucose monitoring devices, known for their reliability and affordability.

Becton, Dickinson and Company

BD provides medical devices and supplies, including povidone-iodine solutions for wound care.

Roche Holding AG

A leader in pharmaceuticals and diagnostics, known for cancer treatments and diagnostic tools.